Aligos Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(24,544) | $27,225 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||
| Accretion of discount on investments | (491) | (1,034) |
| Non cash lease expense | 982 | 905 |
| Change in fair value of 2023 Common Warrants | (6,371) | (63,176) |
| Depreciation expense | 601 | 453 |
| Stock-based compensation including ESPP | 2,678 | 2,119 |
| Changes in operating assets and liabilities: | ||
| Accounts payable | 2,449 | 1,328 |
| Accrued liabilities | 5,170 | (3,352) |
| Operating lease liabilities | (1,665) | (1,499) |
| Other liabilities | (47) | - |
| Deferred revenue | - | 428 |
| Accounts receivable | (27,778) | - |
| Other assets | 938 | 190 |
| Net cash and cash equivalents used in operating activities | (48,078) | (36,413) |
| Cash flows from investing activities: | ||
| Maturities of short-term investments | 60,000 | 20,000 |
| Purchase of short-term investments | - | (103,336) |
| Purchases of property and equipment | (70) | (152) |
| Net cash and cash equivalents provided by (used in) investing activities | 59,930 | (83,488) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with 2025 PIPE offering, net of costs | - | 101,386 |
| Payments on finance lease | (78) | (1) |
| Proceeds from the ESPP purchase | 236 | 180 |
| Net cash and cash equivalents provided by financing activities | 158 | 101,565 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 12,010 | (18,336) |
| Cash, cash equivalents, and restricted cash, beginning of period | 18,413 | 37,107 |
| Cash, cash equivalents, and restricted cash, end of period | $30,423 | $18,771 |
| Supplemental disclosures of noncash financing and investing activities: | ||
| PIPE issuance costs unpaid at period end | - | (41) |
ALIGOS THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.